Eisai, Purdue Join Up To Take Insomnia Drug Into Phase III
This article was originally published in PharmAsia News
Executive Summary
Eisai is teaming up with Purdue for the global development and commercialization of a dual orexin receptor, lemborexant, for insomnia and possibly other potential indications.